BridgeBio Pharma (BBIO) Interest Expenses (2018 - 2026)

BridgeBio Pharma's Interest Expenses history runs 9 years deep, the most recent figure standing at $12.9 million for Q1 2026.

• In Q1 2026, Interest Expenses fell 28.58% year-over-year to $12.9 million; the TTM figure through Mar 2026 stood at $74.0 million (down 13.65% YoY), while the FY2025 annual figure was $53.1 million, down 41.64% from the prior year.
• Interest Expenses came in at $12.9 million for Q1 2026 at BridgeBio Pharma, up from $11.6 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $37.6 million in Q2 2025 to a low of $11.6 million in Q4 2025.
• A 5-year average of $20.3 million and a median of $20.3 million in 2022 frame the typical range for Interest Expenses.
• Across the five-year window, Interest Expenses surged 108.91% in 2022 and plunged 49.1% in 2025, its largest moves.
• BridgeBio Pharma's Interest Expenses stood at $20.0 million in 2022, then climbed by 1.39% to $20.3 million in 2023, then climbed by 6.19% to $21.5 million in 2024, then slumped by 45.93% to $11.6 million in 2025, then climbed by 11.22% to $12.9 million in 2026.
• According to Business Quant data, Interest Expenses over the past three periods registered $12.9 million, $11.6 million, and $11.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison